Kumar Patel, MD
Allergy & Immunology · Tarentum, PANPI 1720198393
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $83,460 of the $123,909 with a category attached, or 67.4%. GSK accounts for 74.2% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2021 at $43,326 and has fallen 73.3% since, to $11,586 in 2025. Among allergy & immunology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,357 payments — averaging $91.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$92K
- Novartis$8K
- AstraZeneca$7K
- Optinose US, Inc.$4K
- Sanofi$3K
- CSL Behring$2K
- plus $9K from 25 others
What the payments were for
- Consulting fees$7,1256%
- Speaking & faculty fees$83,46067%
- Travel & lodging$3,6693%
- Food & beverage$29,18324%
- Education$4710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 381 | $91,918 |
| Novartis | 69 | $7,789 |
| AstraZeneca | 234 | $6,519 |
| Optinose US, Inc. | 37 | $4,387 |
| Sanofi | 78 | $2,509 |
| CSL Behring | 91 | $1,826 |
| Regeneron Healthcare Solutions, Inc. | 89 | $1,690 |
| Amgen(2 entities) | 63 | $1,194 |
| Teva Pharmaceuticals USA, Inc. | 73 | $801 |
| Genentech USA, Inc. | 35 | $755 |
| Biocryst US Sales Co., LLC | 50 | $693 |
| ARS Pharmaceuticals Operations, Inc. | 26 | $566 |
| Kaleo, Inc. | 31 | $525 |
| Boehringer Ingelheim | 33 | $498 |
| Pfizer | 21 | $405 |
| Pharming Healthcare, Inc. | 5 | $375 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $358 |
| Grifols USA, LLC | 2 | $282 |
| Incyte Corporation | 4 | $164 |
| Blueprint Medicines Corporation | 2 | $151 |
| Sanofi-aventis U.S. LLC | 2 | $130 |
| Aimmune Therapeutics, Inc. | 4 | $95 |
| Merck | 4 | $71 |
| Cycle Pharmaceuticals Inc | 3 | $65 |
| Alk-abello, Inc | 2 | $37 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| Mylan Specialty L.p. | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $17 |
| Phadia US Inc. | 1 | $16 |
| Circassia Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$53,461
- Xhance$3,724
- ANORO ELLIPTA$3,600
- DUPIXENT$1,327
- FASENRA$1,217
- TEZSPIRE$903
- NUCALA$895
- BREZTRI$830
- AIRSUPRA$352
- RUCONEST$342
- NEFFY$251
- BEVESPI AEROSPHERE$187
- FARXIGA$187
- Prolastin-C Liquid$151
- SYMBICORT$146
- Xembify$130
- AYVAKIT$124
- ACTIMMUNE$116
- OPZELURA$114
- Hizentra$106
How this compares
$123,909 in reported general payments places this provider in the 90th percentile of 175 allergy & immunology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 186 | $138,750 |
| XolairOmalizumab | 32 | $88,377 |
| Dupixent PenDupilumab | 23 | $85,552 |
| Dupixent SyringeDupilumab | 13 | $50,278 |
| Breo ElliptaFluticasone/Vilanterol | 83 | $35,450 |
| Epinephrine | 111 | $29,517 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 88 | $18,431 |
| Arnuity ElliptaFluticasone Furoate | 64 | $17,539 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $16,428 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 76 | $14,583 |
| Advair HfaFluticasone Propion/Salmeterol | 28 | $12,787 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 335 | $10,388 |
| SymbicortBudesonide/Formoterol Fumarate | 35 | $9,156 |
| Azelastine Hcl | 300 | $8,017 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $6,160 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $91,918 | $191,739333 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $6,519 | $25,58452 claims |
| Boehringer IngelheimCombivent Respimat | $498 | $6,16011 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $801 | $4,01716 claims |
| MerckDulera | $71 | $3,87311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 175 allergy & immunology providers in Pennsylvania.
Other allergy & immunology in Tarentum
- Drew WeissmanPhiladelphia$12.8M
- Eric SchenkelBethlehem$845K
- Sergei BelenkyPittsburgh$775K
- Timothy CraigHershey$564K
- Sandra GawchikUpland$390K
- Anthony RooklinGlen Mills$319K
- Corinna BowserNarberth$229K
- Shailen ShahCollegeville$183K
- Michael PremattaHavertown$168K
- Donald HarperMechanicsburg$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.